Patients face “new normal” of medicines shortages as UK hampered by supply issues and impact of EU exit

Global supply problems have caused a “shock rise” in shortages of life-saving drugs like antibiotics and epilepsy medication, new research reveals today. These shortages come at a cost to the patient and the taxpayer, and are happening despite the NHS spending hundreds of extra millions trying to mitigate the problem. The UK risks being left in the cold when it comes to co-ordinated EU attempts to tackle them. 

That’s according to a new report by the Nuffield Trust think tank and a group of academics, funded by the Health Foundation, which examined key indicators on drug shortages in the UK in the context of global problems with supply chains and the availability of key ingredients. It finds that the past two years have seen constantly elevated medicines shortages, in a "new normal" of frequent disruption to crucial products.  

Key findings on drugs shortages include: 

• Price concessions (where the government gives extra funding because there are no drugs left at the NHS price) have risen sharply in recent months: prior to 2016 there were rarely more than 20 per month but in late 2022 they peaked at 199 and have remained high ever since.  
• The excess cost for medicines in months when they were subject to price concessions was £220m across the year to September 2023.
• There are now over double the number of notifications by drugs companies warning of impending shortages than there were three years ago: in 2023 there were 1,634 such alerts issued, compared to 648 in 2020 (a spike in 2021 was caused by concerns over supply fears in Northern Ireland following Brexit).   
• The UK has been slower to approve drugs than the EU for new drugs that are authorised centrally. Of drugs authorised in the year to December 2023, 56 drugs authorised in Europe were approved later in the UK and eight have not been approved. Four were approved faster.

The report shows that the EU Exit has not caused the recent spike in medicine shortages, but it is likely to significantly weaken the UK’s ability to respond to them by splitting it from European supply chains, authorisations and collective efforts to respond to shortages. In particular, the research highlights the risks posed to the UK from being left out of key initiatives like the Critical Medicines Alliance and Voluntary Solidarity Mechanism, led by EU member states to work together to insulate themselves from the impact of medicines shortages.  

The research, published as part of a wider report supported by the Health Foundation entitled “The future for health after Brexit”, also reveals that Brexit has forced the NHS to rely on ethically dubious sources of migration to shore up its workforce, with recruitment from “red list” countries rising by almost a third in one year; and that life science and medicine regulation is lagging behind the EU.   

Nuffield Trust Brexit Programme Lead, Mark Dayan said:

"The rise in shortages of vital medicines from rare to commonplace has been a shocking development that few would have expected a decade ago. More and more patients across the UK are experiencing a pharmacist telling them that their medication is not available, it may not be available soon, and it may not be available anywhere nearby. This is also creating a great deal of extra work for both GPs and pharmacists.

“We know many of the problems are global and relate to fragile chains of imports from Asia, squeezed by Covid-19 shutdowns, inflation and global instability. Officials in the UK have put in place a much more sophisticated system to monitor and respond, and used extra payments to try to keep products flowing. But exiting the EU has left the UK with several additional problems – products no longer flow as smoothly across the borders with the EU, and in the long term our struggles to approve as many medicines might mean we have fewer alternatives available.”

Professor Tamara Hervey, of the City Law School, said:

“There is nothing inevitable about this ‘new normal’ where Great Britain is isolated in efforts to manage fragilities in global supply of the products and people we need to run the NHS. It is the consequence of policy choices and those could be different. If the Covid-19 pandemic taught us anything, it is that the world is an interconnected place, and having cordial relations with our near neighbours will help us to deliver the health services our population deserves."

The research is based on analysis of freedom of information requests on drug shortages and public data, and informed by a series of interviews and roundtables with experts and top officials. Its authors argue that solving the problems identified will require a more co-operative and proactive approach to EU/UK relations than currently in place and calls on the Government to better anticipate medicine shortages, be more open with patients and the NHS about the prospect of such shortages and better planning on stockpiling drugs.  

Ends.